- FDA approved indications in adults
- Osteoarthritis
- Ankylosing Spondylitis
- Rheumatoid Arthritis
- Acute Pain
- Dysmenorrhea
- Familial Adenoma Polyposis
- FDA approved indications in children
- Juvenile Rheumatoid Arthritis
-
Sulfonamide Allergy
- Immediate Post-Operative CABG state
- See COX2 Inhibitor
- Celecoxib is an NSAID that is more COX2 selective (COX2 Inhibitor)
- Diaryl-substituted pyrazole
- Celecoxib (Celebrex) capsules 50, 100, 200, 400 mg
- Celecoxib capsules may be opened, sprinkled into applesauce and immediately taken with water
-
Osteoarthritis or Ankylosing Spondylitis
- Dose: 200 mg orally daily (or 100 mg orally twice daily)
-
Rheumatoid Arthritis, Acute Pain, Dysmenorrhea
- Dose: 100 to 200 mg orally daily to twice daily
- Familial Adenoma Polyposis
- Dose: 400 mg orally twice daily
- Dosing adjustments
- Decrease dose to 50% in moderate liver dysfunction
-
Juvenile Rheumatoid Arthritis (age 2 to 17 years)
- Weight 10 to 25 kg: 50 mg orally twice daily
- Weight >25 kg: 100 mg orally twice daily
- See NSAID
- Unknown safety in Lactation
- Celecoxib is Pregnancy Category C (except for Category D in third trimester)
- As with NSAIDs, avoid COX2 Inhibitor in pregnancy outside the first part of the second trimester (13 to 20 weeks)
- Teratogenic in first trimester
- Risk of premature ductus arteriosus closure in the fetus in third trimester
- Most NSAIDs carry a legacy system Pregnancy Category B or C designation (aside from third trimester)
- However, many obstetricians avoid NSAIDs entirely in pregnancy (even in second trimester)
- Oral Bioavailability: 22 to 40%
- Half Life: 11 hours
-
CYP2C9 Inhibitors
- Celecoxib levels raised by, for example, Zafirlukast, Fluconazole, and Fluvastatin
- Celecoxib Inhibits CYP2D6
- Increases levels of Beta Blockers, Lithium and other psychotropics
loading